Ironwood Pharmaceuticals, Inc.
IRWD Healthcare Drug Manufacturers Specialty & Generic
Ironwood Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $296.2 million, down 15.7% from fiscal 2024. In the quarter to June 2026, revenue grew 32.6%, EPS grew 106.7%, free cash flow grew 486.7% and total debt was flat, each against the same quarter a year earlier.
Follow IRWD
Ironwood Pharmaceuticals, Inc. (IRWD) EV/Sales
As of 16 October 2026, Ironwood Pharmaceuticals, Inc. (IRWD) trades at a EV/Sales of 2.8×. Over the past ten years it has ranged from 1.9× (September 2025) to 23.8× (January 2015); the current reading is higher than 7% of that period. That is in line with the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.1× | (22.48%) |
| FY2024 | 4.0× | (30.41%) |
| FY2023 | 5.7× | 43.70% |
| FY2022 | 4.0× | (5.44%) |
| FY2021 | 4.2× | (12.93%) |
| FY2020 | 4.8× | (10.16%) |
| FY2019 | 5.4× | 19.36% |
| FY2018 | 4.5× | (35.30%) |
| FY2017 | 7.0× | 2.41% |
| FY2016 | 6.8× | (21.34%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.1× | 18.57% |
| Mar 2026 | 2.6× | (15.98%) |
| Dec 2025 | 3.1× | 59.45% |
| Sep 2025 | 1.9× | (1.78%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLRY Tilray Brands, Inc. compare | 0.6× |
| EVO Evotec AG compare | 0.6× |
| EBS Emergent Biosolutions Inc. compare | 1.0× |
| KMDA Kamada Ltd. compare | 2.1× |
| EOLS Evolus, Inc. compare | 2.1× |
| COLL Collegium Pharmaceutical, Inc. compare | 2.1× |
| IRWD Ironwood Pharmaceuticals, Inc. | 2.8× |
| AQST Aquestive Therapeutics, Inc. compare | 7.9× |
| TKNO Alpha Teknova, Inc. compare | 8.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)